BiotechTube

AGN-193408 SR + AGN-193408 SR

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Open-angle Glaucoma

Conditions

Open-angle Glaucoma, Ocular Hypertension

Trial Timeline

Nov 16, 2020 → Feb 1, 2029

NCT ID
NCT04499248

About AGN-193408 SR + AGN-193408 SR

AGN-193408 SR + AGN-193408 SR is a phase 1/2 stage product being developed by AbbVie for Open-angle Glaucoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04499248. Target conditions include Open-angle Glaucoma, Ocular Hypertension.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04499248Phase 1/2Recruiting

Competing Products

20 competing products in Open-angle Glaucoma

See all competitors
ProductCompanyStageHype Score
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
77
DE-104 ophthalmic solution + DE-104 vehicleSanten PharmaceuticalPhase 2
52
DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicleSanten PharmaceuticalPhase 2
52
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
77
Bimatoprost SRAbbViePhase 3
77
Bimatoprost SR + LUMIGANAbbViePhase 3
77
Bimatoprost (SR)AbbViePhase 3
77
Bimatoprost Sustained Release ImplantAbbViePre-clinical
23
Bimatoprost SR + Sham Bimatoprost SRAbbViePhase 3
77
Preservative-Free Tafluprost + Comparator: timololMerckPhase 3
77
Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension + Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution + Subject's habitual PGA monotherapyNovartisApproved
85
Placebo + RO5093151RochePhase 2
52
0.01% RO7058584 + 0.1% RO7058584 + 1% RO7058584 + Matching Placebo + Latanoprost 0.005%RochePhase 1
33
XalacomPfizerPhase 3
76
XalatanPfizerPhase 2
51
LatanoprostPfizerApproved
84
PF-04217329 - Lowest Dose + PF-04217329 - Low Dose + PF-04217329 - Middle Dose + PF-04217329 - High Middle Dose + PF-04217329 - High Dose + PF-4217329 - Highest Dose + PF-04217329 - Vehicle + Latanoprost Vehicle + PF-04217329 - Low Dose + Latanoprost Vehicle + PF-04217329 - Middle Dose + Latanoprost Vehicle + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Low Dose + Latanoprost 0.005% + PF-04217329 - Middle Dose + Latanoprost 0.005% + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - VehiclePfizerPhase 2
51
XalacomPfizerPre-clinical
22
Xalacom + Xalatan + TimololPfizerPhase 3
76
PF-04217329 + latanoprost vehicle + PF-04217329 + latanoprostPfizerPhase 2
51

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85